Jahn, Stephan Wenzel http://orcid.org/0000-0002-0330-0274
Bösl, Andreas
Tsybrovskyy, Oleksiy
Gruber-Rossipal, Christine
Helfgott, Ruth
Fitzal, Florian
Knauer, Michael
Balic, Marija
Jasarevic, Zerina
Offner, Felix
Moinfar, Farid
Funding for this research was provided by:
Syvidon Diagnostics GmbH, Cologne Germany and Myriad Service GmbH, Munich Germany
Article History
Received: 25 October 2019
Revised: 1 March 2020
Accepted: 26 March 2020
First Online: 27 April 2020
Ethics approval and consent to participate
: The study received ethics approval by the ethics committee (approval number 31/09) of the Ordensklinikum/Hospital of the Sisters of Charity, Linz Austria. Requirement of the patients to provide informed consent in order to participate in the study was waived by the ethics board approval. The study was performed in accordance with the Declaration of Helsinki.
: Data used for analysis are listed in Supplemental Table 4.
: One author (K.M.) declares competing interests through involvement in the ongoing Phase III study (SAKK 23/16): “Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial” The study receives funding from Agendia, Europe. The author does not receive any personal financial contributions or advantages due to his participation in the study.
: Part of the funding for this study was provided by Sividon Diagnostics GmbH, Cologne, Germany and Myriad Service GmbH, Munich, Germany. The companies had no influence on the study design, on the interpretation or on the publication of the data of this study.